Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | RASGRP3 | Q8IV61 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23600907 | 0.83 | PADI4 (0.33) | PADI4CTDSP1 | |
| SCHEMBL22735021 | 0.82 | HSP90AA1 (0.47) | PADI4PRKCAPRKCERASGRP3HSP90AA1 | |
| SCHEMBL18707135 | 0.80 | CA12 (0.45) | P2RX7 | |
| SCHEMBL18707137 | 0.80 | CA12 (0.45) | P2RX7 | |
| SCHEMBL15764960 | 0.77 | CA12 (0.49) | CTDSP1 | |
| SCHEMBL22735131 | 0.74 | RAB9A (0.58) | — | |
| SCHEMBL21039220 | 0.74 | NPC1 (0.34) | PADI4 | |
| SCHEMBL2491722 | 0.73 | KDM4E (0.46) | PADI4CYP11B2P2RX7HSP90AA1 | |
| SCHEMBL2491724 | 0.73 | KDM4E (0.46) | PADI4CYP11B2P2RX7HSP90AA1 | |
| SCHEMBL21040509 | 0.73 | JUN (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | PADI4 1078/4885CYP11B2 3248/4885CTDSP1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.